The pioneering growth capital fund is the largest dedicated to biopharma and medtech companies seeking scale-up financing in Europe With over €2 billion under management, Sofinnova Partners continues its expansion across the entire value chain of life sciences investments, from seed to later-stage PARIS, France – M...
- Michelin Group and the Canadian firm Pyrowave join forces to accelerate time-to-market for an innovative plastic waste recycling technology. - They agree to fast track the process industrialization. - The purpose of the technology is to increase the rate of sustainable materials not only in Michelin tires, but al...
IDE Approval Clears Path to U.S. Clinical Trial Launch for Vascular Sealant TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has received approval from the U.S. Food and Drug Administration for its Investigational Device Exemption...
● Start-up from Imperial College London and the Francis Crick Institute brings together 15 years of world-leading research on N-myristoyltransferase (NMT) and breakthrough discoveries related to its inhibition in cancer ● Initial financing of £4.5M from venture capital syndicate of experienced life sciences investo...
Nov 8, 2020, Calliditas Therapeutics AB (OMX Nasdaq: CALTX, NASDAQ: CALT) (”Calliditas”) today announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon® versus placebo in patients with primary IgA nephropathy (IgAN).
Paris, France, Tuesday, November 3, 2020, 7.30 am CET GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported tha...
Daix (France), November 2, 2020 Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medica...
Alderley Park, 27 October 2020, Redx Pharma plc (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, is pleased to announce that it has appointed Dr Jane Robertson as Chief Medical Officer. Jane is a well respected UK haemato-oncologist with over 17 years' experience of clin...
October 22, 2020 12:30 AM Eastern Daylight Time PARIS--BUSINESS WIRE --Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the "Company"), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative di...
CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE) CinCor Pharma, Inc. (“CinCor”), a clinical-stage biopharmaceutical company developing medications targeting cardiovascular disease, announced today that they have dosed the first subject in the brigHTN study. The brigHTN study is a Phase 2 clinical trial evaluating the ...
Dr. Anderson’s appointment as Partner in the Crossover Fund reflects the venture capital firm’s continuing expansion across the entire value chain of life sciences investments, from seed to later-stage PARIS, France – October 14, 2020 Sofinnova Partners, a leading European life sciences venture capital firm ba...
© 2020 Sofinnova Partners TERMS AND CONDITIONS